In summary, this study demonstrated that local IL-12 immunotherapy enhanced the killing of radio-resistant prostate tumors, increased the coverage of vessels by α-SMA+ pericytes, and enhanced the vascular perfusion. Here, ACTA1 is linked to prostate neoplasm.